trending Market Intelligence /marketintelligence/en/news-insights/trending/is7v9XfD6ns0SgUUcin_HQ2 content esgSubNav
In This List

Aeterna Zentaris initiates strategic review

Blog

Insight Weekly: M&A outlook; US community bank margins; green hydrogen players' EU expansion

Blog

Global M&A by the Numbers: Q2 2022

Blog

Insight Weekly: US bank M&A; low refinancing eases rates impact; Texas crypto mining booms

Blog

Infographic 2022 Top Tech Trends Shaping Corporations


Aeterna Zentaris initiates strategic review

Aeterna Zentaris Inc. formed a special board committee to review strategic options.

The review process may result in different outcomes or no outcome, the company noted. In addition, there is no guarantee that the company will pursue or execute transactions.

Macrilen, or macimorelin, is the company's medicine approved for diagnosing adult growth hormone deficiency in the EU and U.S. Adult growth hormone deficiency, or AGHD, occurs when the body's anterior pituitary gland does not produce enough growth hormone.

Summerville, S.C.-based Aeterna Zentaris is engaged in developing pharmaceutical products that address unmet medical needs of patients with rare endocrine diseases.

Torreya is acting as the company's financial adviser in the strategic review.